Grumabix (Abiraterone Acetate)

Grumabix is indicated for patients with metastatic castration‑resistant prostate cancer (mCRPC) who have progressed despite androgen‑deprivation therapy.

• In combination with prednisone to mitigate mineralocorticoid‑related side effects.
• As part of a systemic therapy regimen after chemotherapy failure.
• For use in men whose disease is driven by androgen signaling.
• May be considered when other androgen biosynthesis inhibitors are unsuitable.

The safety profile of Grumabix includes a range of adverse events that vary in frequency and severity.

Common

• Fatigue or weakness.
• Joint and muscle pain (arthralgia, myalgia).
• Fluid retention (edema).

Serious

• Liver enzyme elevations.
• Severe hypertension.
• Low potassium (hypokalemia).

Before initiating Grumabix, clinicians should evaluate several clinical factors to reduce the risk of complications.

• Assess liver function tests and monitor them regularly during therapy.
• Check baseline blood pressure and electrolytes, especially potassium levels.
• Use concomitant low‑dose prednisone to prevent mineralocorticoid excess.
• Avoid use in patients with uncontrolled hypertension or active cardiovascular disease.
• Counsel patients on the importance of adherence to steroid therapy to prevent adrenal insufficiency.
• Review any history of liver disease or hepatitis before prescribing.

Grumabix can interact with other medicines, affecting its efficacy or safety.

Avoid

• Strong CYP3A4 inducers such as rifampin, carbamazepine, or phenytoin, which may lower abiraterone levels.
• Concurrent use of other androgen biosynthesis inhibitors without medical supervision.

Use with caution

• Antihypertensive agents, as Grumabix may increase blood pressure.
• Antifungal azoles (e.g., ketoconazole, itraconazole) that inhibit CYP3A4 and could raise drug concentrations.
• Medications that affect potassium balance, such as diuretics.